{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:31:57Z","timestamp":1785774717224,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejpb.2023.05.005","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:38:20Z","timestamp":1683826700000},"page":"100-107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Preclinical characterization of water-free cyclosporine eye drops \u2013 Factors impacting ocular penetration ex vivo and in vivo"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3831-3833","authenticated-orcid":false,"given":"Priyanka","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2823-4007","authenticated-orcid":false,"given":"Johannes","family":"Korward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2049-2076","authenticated-orcid":false,"given":"Sonja","family":"Kr\u00f6sser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5997-5994","authenticated-orcid":false,"given":"Ilva D.","family":"Rupenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.05.005_b0005","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf."},{"key":"10.1016\/j.ejpb.2023.05.005_b0010","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf."},{"key":"10.1016\/j.ejpb.2023.05.005_b0015","first-page":"90","article-title":"Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A","volume":"42","author":"Brignole","year":"2001","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"10.1016\/j.ejpb.2023.05.005_b0020","first-page":"28","article-title":"Regulation of human leukocyte antigen expression in human conjunctival epithelium","volume":"40","author":"Tsubota","year":"1999","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2023.05.005_b0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1155\/2013\/636812","article-title":"Modulation of conjunctival goblet cell function by inflammatory cytokines","volume":"2013","author":"Contreras-Ruiz","year":"2013","journal-title":"Mediators of Inflammation."},{"key":"10.1016\/j.ejpb.2023.05.005_b0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1167\/iovs.07-0569","article-title":"Hyperosmolarity-induced cornification of human corneal epithelial cells is regulated by JNK MAPK","volume":"49","author":"Chen","year":"2008","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"10.1016\/j.ejpb.2023.05.005_b0035","doi-asserted-by":"crossref","DOI":"10.1136\/bjophthalmol-2015-307415","article-title":"Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction","author":"Baudouin","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2023.05.005_b0040","doi-asserted-by":"crossref","unstructured":"C. Baudouin, P. Aragona, E.M. Messmer, A. Tomlinson, M. Calonge, Boboridis KG, et al., Role of Hyperosmolarity in the Pathogenesis and Management of Dry Eye Disease: Proceedings of the OCEAN Group Meeting, Ocul Surf. 11 (2013) 246\u201358, 10.1016\/j.jtos.2013.07.003.","DOI":"10.1016\/j.jtos.2013.07.003"},{"key":"10.1016\/j.ejpb.2023.05.005_b0045","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00003226-199811000-00002","article-title":"The pathology of dry eye: the interaction between the ocular surface and lacrimal glands","volume":"17","author":"Stern","year":"1998","journal-title":"Cornea."},{"key":"10.1016\/j.ejpb.2023.05.005_b0050","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0161-6420(98)99043-1","article-title":"A randomized, placebo-controlled trial of topical cyclosporin a in steroid-dependent atopic keratoconjunctivitis1","volume":"105","author":"Hingorani","year":"1998","journal-title":"Ophthalmology."},{"key":"10.1016\/j.ejpb.2023.05.005_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00588","article-title":"Lessons to learn from low-dose cyclosporin-A: a new approach for unexpected clinical applications","volume":"10","author":"Flores","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.ejpb.2023.05.005_b0060","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3109\/09273948.2010.498657","article-title":"Clinical review: topical ophthalmic use of cyclosporin A","volume":"18","author":"Utine","year":"2010","journal-title":"Ocular Immunol. Inflam."},{"key":"10.1016\/j.ejpb.2023.05.005_b0065","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/OPTH.S1409","article-title":"Treatment of chronic dry eye: focus on cyclosporine","volume":"2","author":"Kymionis","year":"2008","journal-title":"Clin Ophthalmol."},{"key":"10.1016\/j.ejpb.2023.05.005_b0070","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.drudis.2016.04.002","article-title":"Modern approaches to the ocular delivery of cyclosporine A","volume":"21","author":"Agarwal","year":"2016","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.ejpb.2023.05.005_b0075","first-page":"16","article-title":"Successfully improving ocular drug delivery using the cationic nanoemulsion","volume":"2012","author":"Lallemand","year":"2012","journal-title":"Novasorb, J Drug Deliv."},{"key":"10.1016\/j.ejpb.2023.05.005_b0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0939-6411(03)00138-3","article-title":"Cyclosporine A delivery to the eye: a pharmaceutical challenge","volume":"56","author":"Lallemand","year":"2003","journal-title":"Eur J Pharm Biopharm."},{"key":"10.1016\/j.ejpb.2023.05.005_b0085","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II iatrogenic report","volume":"15","author":"Gomes","year":"2017","journal-title":"Ocul Surf."},{"key":"10.1016\/j.ejpb.2023.05.005_b0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jtos.2019.02.010","article-title":"Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics","volume":"17","author":"Agarwal","year":"2019","journal-title":"Ocul Surf."},{"key":"10.1016\/j.ejpb.2023.05.005_b0095","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00417-016-3572-y","article-title":"A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye","volume":"255","author":"Gehlsen","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"10.1016\/j.ejpb.2023.05.005_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2019.110564","article-title":"Perfluorohexyloctane (F6H8) as a delivery agent for cyclosporine A in dry eye syndrome therapy \u2013 langmuir monolayer study complemented with infrared nanospectroscopy","volume":"184","author":"Chachaj-Brekiesz","year":"2019","journal-title":"Colloids and Surfaces B: Biointerfaces."},{"key":"10.1016\/j.ejpb.2023.05.005_b0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejpb.2014.05.009","article-title":"Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery","volume":"88","author":"Dutescu","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.05.005_b0110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpb.2019.06.008","article-title":"Topical semifluorinated alkane-based azithromycin suspension for the management of ocular infections","volume":"142","author":"Agarwal","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.05.005_b0115","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1089\/jop.2015.0048","article-title":"Semifluorinated alkane eye drops for treatment of dry eye disease\u2013a prospective","volume":"31","author":"Steven","year":"2015","journal-title":"Multicenter Noninterventional. Study, J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2023.05.005_b0120","first-page":"50","article-title":"Semifluorinated alkane eye drops in chronic ocular graft-versus-host disease: a prospective","volume":"63","author":"Eberwein","year":"2020","journal-title":"Multicenter, Noninterventional Study, Ophthalmic Research."},{"key":"10.1016\/j.ejpb.2023.05.005_b0125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2018.01.019","article-title":"Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs","volume":"538","author":"Agarwal","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.05.005_b0130","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/ICO.0000000000002633","article-title":"A water-free 0.1% cyclosporine A solution for treatment of dry eye disease: results of the randomized phase 2B\/3 ESSENCE study","volume":"40","author":"Sheppard","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.ejpb.2023.05.005_b0135","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","article-title":"A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease","volume":"126","author":"Wirta","year":"2019","journal-title":"Ophthalmology."},{"key":"10.1016\/j.ejpb.2023.05.005_b0140","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.ejpb.2023.05.005_b0145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1745-6673-3-26","article-title":"Safety evaluation of topical applications of ethanol on the skin and inside the oral cavity","volume":"3","author":"Lachenmeier","year":"2008","journal-title":"J. Occup. Med. Toxicol."},{"key":"10.1016\/j.ejpb.2023.05.005_b0150","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.1039\/D0RA01692F","article-title":"Molecular mechanism of the skin permeation enhancing effect of ethanol: a molecular dynamics study","volume":"10","author":"Gupta","year":"2020","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejpb.2023.05.005_b0155","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2005.11.020","article-title":"W\/O microemulsions for ocular delivery: evaluation of ocular irritation and precorneal retention","volume":"111","author":"Alany","year":"2006","journal-title":"J. Control Release."},{"key":"10.1016\/j.ejpb.2023.05.005_b0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0939-6411(02)00036-X","article-title":"Optimisation of carbomer viscous eye drops: an in vitro experimental design approach using rheological techniques","volume":"54","author":"Ceulemans","year":"2002","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.05.005_b0165","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0278-6915(85)90030-4","article-title":"Hen's egg chorioallantoic membrane test for irritation potential","volume":"23","author":"Luepke","year":"1985","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.ejpb.2023.05.005_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2012.04.063","article-title":"Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen's egg chorioallantoic membrane and excised bovine cornea models","volume":"432","author":"Abdelkader","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.05.005_b0175","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0272-0590(91)90246-Z","article-title":"Evaluation of seven in vitro alternatives for ocular safety testing","volume":"17","author":"Bruner","year":"1991","journal-title":"Fundam. Appl. Toxicol."},{"key":"10.1016\/j.ejpb.2023.05.005_b0180","unstructured":"P. Weterings, Y.H. M. Vanerp, Validation of the BECAM assay - An eye irritancy screening test, Pharmaceutisch weekblad-scientific edition, Royal Dutch Assoc, 1987."},{"key":"10.1016\/j.ejpb.2023.05.005_b0185","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1208\/s12249-021-02050-6","article-title":"Ocular distribution of papaverine using non-aqueous vehicles","volume":"22","author":"Agarwal","year":"2021","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2023.05.005_b0190","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1089\/jop.2017.0042","article-title":"Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease","volume":"33","author":"Steven","year":"2017","journal-title":"J Ocul Pharmacol Ther."},{"key":"10.1016\/j.ejpb.2023.05.005_b0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejpb.2005.01.009","article-title":"Cell culture models of the ocular barriers","volume":"60","author":"Hornof","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.05.005_b0200","doi-asserted-by":"crossref","unstructured":"S.-i. Yasueda, M. Higashiyama, M. Yamaguchi, A. Isowaki, A. Ohtori, Corneal critical barrier against the penetration of dexamethasone and lomefloxacin hydrochloride: evaluation by the activation energy for drug partition and diffusion in cornea, Drug Dev Ind Pharm. (2007) 33, 805-11, 10.1080\/03639040701377995.","DOI":"10.1080\/03639040701377995"},{"key":"10.1016\/j.ejpb.2023.05.005_b0205","doi-asserted-by":"crossref","unstructured":"P. Daull, F. Lallemand, B. Philips, G. Lambert, R. Buggage, J.-S. Garrigue, Distribution of cyclosporine a in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits, Cornea (2013) 32.","DOI":"10.1097\/ICO.0b013e31825e83f4"},{"key":"10.1016\/j.ejpb.2023.05.005_b0210","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2165\/00003088-199529020-00006","article-title":"Clinical pharmacokinetics of various topical ophthalmic delivery systems","volume":"29","author":"Frangie","year":"1995","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2023.05.005_b0215","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/pharmaceutics4010243","article-title":"Ophthalmic drug delivery in glaucoma\u2014a review","volume":"4","author":"Januleviciene","year":"2012","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2023.05.005_b0220","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0002-9394(86)90771-3","article-title":"Drop size of commercial glaucoma medications","volume":"101","author":"Lederer","year":"1986","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2023.05.005_b0225","article-title":"3rd, An evaluation of how glaucoma patients use topical medications: a pilot study","volume":"105","author":"Tsai","year":"2007","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"10.1016\/j.ejpb.2023.05.005_b0230","doi-asserted-by":"crossref","unstructured":"S. Nagataki, S. Mishima, Pharmacokinetics of instilled drugs in the human eye, Int Ophthalmol Clin. (1980) 20.","DOI":"10.1097\/00004397-198002030-00006"},{"key":"10.1016\/j.ejpb.2023.05.005_b0235","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/archopht.1980.01020030114010","article-title":"Topically applied pilocarpine: human pupillary response as a function of drop size","volume":"98","author":"File","year":"1980","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejpb.2023.05.005_b0240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0169-409X(95)00010-5","article-title":"Ocular absorption following topical delivery","volume":"16","author":"J\u00e4rvinen","year":"1995","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.05.005_b0245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/jop.1986.2.67","article-title":"Topical ocular drug delivery: recent developments and future challenges","volume":"2","author":"Lee","year":"1986","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2023.05.005_b0250","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1081\/PDT-100102035","article-title":"Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution","volume":"5","author":"Klang","year":"2000","journal-title":"Pharm Dev Technol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:52:31Z","timestamp":1760547151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123001194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":50,"alternative-id":["S0939641123001194"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.05.005","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical characterization of water-free cyclosporine eye drops \u2013 Factors impacting ocular penetration ex vivo and in vivo","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}